Nat Nanotechnol:新疫苗可提高抗体浓度和效果

2014-02-13 张笑 中国科学报

科学家在《自然—纳米技术》上报告称,他们研发出一种维持毒素结构的疫苗会改善疫苗效果。 在未激活毒素基础上研制出的疫苗通常用来在不会导致病人病情加重的情况下,刺激产生针对比如大肠杆菌等细菌感染的免疫反应。一般我们利用化学手段或者加热方式让毒素失去活性,但是,这可能导致其结构改变,从而让疫苗失效。 Liangfang Zhang等人设计出一种方法,可通过采用外覆盖血红细胞膜的纳米粒子捕捉毒素的方式

科学家在《自然—纳米技术》上报告称,他们研发出一种维持毒素结构的疫苗会改善疫苗效果。

在未激活毒素基础上研制出的疫苗通常用来在不会导致病人病情加重的情况下,刺激产生针对比如大肠杆菌等细菌感染的免疫反应。一般我们利用化学手段或者加热方式让毒素失去活性,但是,这可能导致其结构改变,从而让疫苗失效。

Liangfang Zhang等人设计出一种方法,可通过采用外覆盖血红细胞膜的纳米粒子捕捉毒素的方式保留葡萄球菌α-溶血素的毒性结构。捕捉过程可保证毒素的毒性被中和,且仍然维持其诱导免疫反应的功能。

Zhang等人将上述方法获取的含有已失活毒素的疫苗与对照疫苗分别注入小鼠皮肤中,对比了其安全性和有效性。他们发现用纳米粒子研制的疫苗比对照疫苗产生更高浓度的抗体,所产生的抗体对中和毒素也更有效。在此效率提高的影响下,注射对照疫苗的小鼠成活率为90%,而注射新疫苗的小鼠成活率达到了100%。

原始出处

Hu CM, Fang RH, Luk BT, Zhang L.Nanoparticle-detained toxins for safe and effective vaccination.Nat Nanotechnol. 2013 Dec

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1652096, encodeId=1c601652096b6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Aug 24 06:41:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693211, encodeId=5f8216932112e, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Thu Nov 27 00:41:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879912, encodeId=f8a318e99121f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 14 06:41:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544381, encodeId=fa0d1544381b0, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sat Feb 15 01:41:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
    2014-08-24 shock_melon
  2. [GetPortalCommentsPageByObjectIdResponse(id=1652096, encodeId=1c601652096b6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Aug 24 06:41:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693211, encodeId=5f8216932112e, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Thu Nov 27 00:41:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879912, encodeId=f8a318e99121f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 14 06:41:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544381, encodeId=fa0d1544381b0, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sat Feb 15 01:41:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
    2014-11-27 gous
  3. [GetPortalCommentsPageByObjectIdResponse(id=1652096, encodeId=1c601652096b6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Aug 24 06:41:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693211, encodeId=5f8216932112e, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Thu Nov 27 00:41:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879912, encodeId=f8a318e99121f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 14 06:41:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544381, encodeId=fa0d1544381b0, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sat Feb 15 01:41:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]
    2014-09-14 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1652096, encodeId=1c601652096b6, content=<a href='/topic/show?id=13d01e24509' target=_blank style='color:#2F92EE;'>#TEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17245, encryptionId=13d01e24509, topicName=TEC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852f24292001, createdName=shock_melon, createdTime=Sun Aug 24 06:41:00 CST 2014, time=2014-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1693211, encodeId=5f8216932112e, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Thu Nov 27 00:41:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879912, encodeId=f8a318e99121f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Sep 14 06:41:00 CST 2014, time=2014-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544381, encodeId=fa0d1544381b0, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Sat Feb 15 01:41:00 CST 2014, time=2014-02-15, status=1, ipAttribution=)]

相关资讯

JID:脊髓灰质炎新疫苗DTaP-sIPV安全有效

虽然口服脊髓灰质炎疫苗大大降低了全球感染野生型脊髓灰质炎病毒的人数,但是它可能引起疫苗相关性瘫痪型脊髓灰质炎(VAPP, vaccine-associated paralytic poliomyelitis)和疫苗衍生脊髓灰质炎病毒(VDPVs, vaccine-derived polioviruse)所致的脊髓灰质炎的蔓延。而新的灭活脊髓灰质炎病毒,如减毒的Sabin病毒株(sIPV, inac